- Home
- CJET vs BIAF Comparison
CJET vs BIAF Comparison
Compare CJET & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- BIAF
- Stock Information
- Founded
- CJET 2009
- BIAF 2014
- Country
- CJET China
- BIAF United States
- Employees
- CJET N/A
- BIAF N/A
- Industry
- CJET Auto Manufacturing
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CJET Consumer Discretionary
- BIAF Health Care
- Exchange
- CJET Nasdaq
- BIAF Nasdaq
- Market Cap
- CJET 14.3M
- BIAF 14.5M
- IPO Year
- CJET N/A
- BIAF 2022
- Fundamental
- Price
- CJET $1.76
- BIAF $0.68
- Analyst Decision
- CJET
- BIAF Strong Buy
- Analyst Count
- CJET 0
- BIAF 1
- Target Price
- CJET N/A
- BIAF $6.00
- AVG Volume (30 Days)
- CJET 69.5K
- BIAF 313.4K
- Earning Date
- CJET 01-28-2025
- BIAF 11-14-2024
- Dividend Yield
- CJET N/A
- BIAF N/A
- EPS Growth
- CJET N/A
- BIAF N/A
- EPS
- CJET N/A
- BIAF N/A
- Revenue
- CJET $10,275,000.00
- BIAF $9,367,785.00
- Revenue This Year
- CJET N/A
- BIAF $285.51
- Revenue Next Year
- CJET N/A
- BIAF $20.05
- P/E Ratio
- CJET N/A
- BIAF N/A
- Revenue Growth
- CJET 31.31
- BIAF 2813.87
- 52 Week Low
- CJET $1.65
- BIAF $0.66
- 52 Week High
- CJET $23.94
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- CJET 37.95
- BIAF 26.89
- Support Level
- CJET $1.93
- BIAF $0.67
- Resistance Level
- CJET $2.08
- BIAF $1.01
- Average True Range (ATR)
- CJET 0.17
- BIAF 0.08
- MACD
- CJET -0.06
- BIAF -0.01
- Stochastic Oscillator
- CJET 10.71
- BIAF 4.29
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.